NOOM

Saeju Jeong and Artem Petakov met at a hackathon in New York in 2008. Jeong had grown up in South Korea watching his parents struggle with their health and had zero interest in building another to-do app.

He wanted to build something that actually changed behavior. Not just tracked it.

The original version wasn't even a weight loss product — it was a broader wellness platform called 'WorkSmart Labs' that experimented with mobile health tools before smartphones were ubiquitous.

By 2012, they'd zeroed in on weight loss because that's where the pain was most acute and people were most willing to pay. They rebranded to Noom and started building what they called 'psychology-based weight loss' — borrowing frameworks from cognitive behavioral therapy and combining them with food logging, step tracking, and one-on-one coaching.

The coaching was the differentiator. Not a robot.

An actual human, pinging you through the app.

They spent years bootstrapping and grinding through the noisy fitness app market before landing meaningful funding. The pitch was clever: we're not a diet app, we're a behavior change company.

That framing opened doors that MyFitnessPal couldn't walk through.

Noom runs on a subscription model. Users pay somewhere between $40 and $70 a month (depending on plan length) for access to the app, daily lessons based on cognitive behavioral therapy principles, a food logging database, a step counter, and access to a human health coach over chat.

The product is built around psychology, not calorie math. The signature feature is color-coding foods as green, yellow, or red based on calorie density — not 'good' or 'bad,' they're very careful about that framing.

Daily bite-sized lessons nudge users toward understanding why they overeat, not just what they overeat. It's the difference between a gym and a therapist who occasionally recommends the gym.

The coaching is the expensive part. Noom employs (or contracts) thousands of coaches — health coaches, not registered dietitians — to manage groups of users through the app.

One coach typically handles multiple groups simultaneously, which keeps costs manageable but has drawn criticism over quality and availability. At scale, the margin math works if people stay subscribed for three to six months.

The churn challenge is that Noom often works — so people lose the weight, hit their goal, and cancel.

The core product is the Noom Weight program — a 16-to-28-week structured course combining daily psychology-based lessons, food logging with the green-yellow-red color system, group challenges, and access to a personal health coach over in-app chat. It's the flagship and still the main revenue driver.

Noom Mood is a companion mental health program that applies the same CBT-lite framework to stress and anxiety management. It launched in 2021 and broadened the addressable market beyond weight loss, though it hasn't had the same traction.

Noom Med is the newer, higher-stakes bet. Launched in 2023, it offers telehealth consultations and prescriptions for GLP-1 medications like semaglutide (the active ingredient in Ozempic and Wegovy) — positioned as a medically supervised weight loss program that combines drug therapy with behavioral coaching.

It's a direct response to the GLP-1 wave and signals that Noom knows it can't fight the drugs, so it's trying to sit alongside them instead.

Noom's growth story is basically a masterclass in Facebook ads and a cautionary tale about them at the same time. At their peak, Noom was one of the largest buyers of Facebook and Instagram advertising in the direct-to-consumer health space.

The funnel was surgical: run ads targeting people who'd recently searched for weight loss, push them through a long-form quiz that felt personalized (it kind of was), end on a low introductory price offer for a two-week trial, and auto-enroll in a full subscription.

The quiz was the real hack. By the time you'd answered 20 questions about your height, weight, age, goals, and emotional relationship with food, you felt like Noom had been built specifically for you.

Conversion rates on that quiz funnel were exceptional. The psychological buy-in happened before a user ever logged their first meal.

The celebrity health wave also helped. When GLP-1 drugs like Ozempic started dominating headlines in 2022 and 2023, Noom pivoted aggressively — launching Noom Med, a telehealth service offering GLP-1 prescriptions.

That move was either brilliant or desperate depending on your view. It kept Noom relevant in a moment when standalone behavior-change apps looked suddenly underpowered next to a weekly injection.

The FTC and the class-action lawsuit were the two-punch combination Noom didn't see coming clearly enough. In 2023, Noom agreed to pay $62 million to settle FTC allegations over deceptive subscription practices — specifically that they made it extremely difficult to cancel, buried the auto-renewal terms, and trained support staff to delay cancellations.

The settlement was one of the largest ever in the subscription app space.

The cancellation issue was real and documented extensively by users online. The trial was cheap, the cancellation button was not obvious, and customer service response times conveniently stretched beyond the refund window.

Whether that was intentional policy or bad UX is the kind of question regulators don't wait around for the company to answer.

The deeper challenge is structural. Behavior change is genuinely hard to sustain at scale, and Noom's coaching model is expensive relative to pure software margins.

Competitors with no coaches — Cronometer, MyFitnessPal, Lose It — charge far less or nothing. And GLP-1 drugs have reframed the entire weight loss market: if Ozempic can do what therapy couldn't, what's the long-term addressable market for a psychology-based app?

That question doesn't have a clean answer yet, and it's the one keeping investors from pricing in a premium.

Noom raised $659 million across several rounds, with the biggest check coming from Silver Lake — the private equity giant — which led a $540 million Series F in 2021 that valued the company at $3.7 billion. That valuation put Noom squarely in unicorn territory and set up what looked like a near-term IPO.

The IPO never happened.

Earlier backers included Sequoia Capital, which participated in earlier rounds and gave Noom the credibility stamp that opened subsequent doors. RRE Ventures and Samsung Ventures were also early supporters, with Samsung's involvement reflecting interest from the hardware side of health tech — wearables, health monitoring — where Noom's behavioral data was potentially valuable.

The Silver Lake round was the defining moment. $540 million in a single check, overwhelmingly for a behavior-change subscription app, right at the peak of the DTC health boom.

It bought Noom time to expand into GLP-1 telehealth and survive the FTC settlement without a liquidity crisis. Whether Silver Lake gets their money back is the open question hanging over the whole company.